Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical breakdown of AndroGel's FDA approval history, current compounding legal status under 503A and 503B pathways, label requirements, and safety considerations for compounded testosterone gel.
Read clinical reviewA detailed comparison of how the FDA and EMA regulate AndroGel (testosterone gel), including approval history, cardiovascular safety reviews, label restrictions, and post-market surveillance differences.
Read clinical reviewA clinical review of AndroGel (testosterone gel) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, transference risk, and regulatory label changes.
Read clinical reviewA complete timeline of AndroGel (testosterone gel 1%) FDA label revisions from 2020 through 2026, covering cardiovascular warnings, REMS modifications, transfer risk language, and post-market surveillance findings.
Read clinical reviewA clinical review of AndroGel's regulatory history, patent disputes, Paragraph IV litigation, FDA label changes, and cardiovascular safety controversies from approval through post-market surveillance.
Read clinical reviewA clinical review of AndroGel's regulatory history, current label requirements, post-market safety data, and the next-generation testosterone formulations in development or recently approved.
Read clinical review